PharmAust Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II cli… Read more
PharmAust Ltd - Asset Resilience Ratio
PharmAust Ltd (ECQ) has an Asset Resilience Ratio of 0.05% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2019)
This chart shows how PharmAust Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down PharmAust Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €4.29K | 0.05% |
| Total Liquid Assets | €4.29K | 0.05% |
Asset Resilience Insights
- Limited Liquidity: PharmAust Ltd maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PharmAust Ltd Industry Peers by Asset Resilience Ratio
Compare PharmAust Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for PharmAust Ltd (2014–2019)
The table below shows the annual Asset Resilience Ratio data for PharmAust Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-06-30 | 0.05% | €4.29K | €8.60 Million | -0.03pp |
| 2018-06-30 | 0.08% | €6.27K | €8.36 Million | +0.02pp |
| 2017-06-30 | 0.05% | €4.29K | €8.20 Million | -0.02pp |
| 2016-06-30 | 0.07% | €4.25K | €6.26 Million | +0.02pp |
| 2015-06-30 | 0.05% | €4.29K | €9.52 Million | +0.03pp |
| 2014-06-30 | 0.02% | €1.57K | €8.21 Million | -- |